FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2033965404> ?p ?o ?g. }

• W2033965404 endingPage "269" @default.
• W2033965404 startingPage "261" @default.
• W2033965404 abstract "The ideal treatment of patients with primary membranous nephropathy (MN) and persistent nephrotic syndrome (NS) is still a matter of debate. This is a major issue since these patients may progress to end-stage kidney disease (ESKD) in 5-10 years. Steroids, alkylating agents, and calcineurin inhibitors have been suggested to achieve NS remission and prevent ESKD in this population. Treatment benefits, however, are uncertain and are often offset by serious adverse events (SAEs). Evidence that B cells play a crucial role in the pathogenesis of the disease, both as precursors of autoantibody-producing cells and as antigen-presenting cells, provided the background for explorative studies testing the role of B cell-depletion therapy with the monoclonal antibody rituximab. This approach aimed at selectively inhibiting disease mechanisms without the devastating consequences of unspecific immunosuppression. Finding that rituximab safely ameliorated NS in 8 patients with primary MN fueled a series of observational studies that uniformly confirmed the safety/efficacy profile of rituximab in this context. Although head-to-head comparisons in randomized clinical trials are missing, comparative analyses between series of homogeneous patient cohorts clearly show at least similar efficacy of rituximab as compared to steroid plus alkylating agents. Moreover, data confirm the dramatically superior safety profile of rituximab that actually appears to be associated with a rate of SAEs even lower than that observed with conservative therapy. Rituximab is also effective in patients resistant to other treatments and its cost-effectiveness is further increased when treatment is titrated to circulating B cells. Recently identified pathogenic antibodies against the M type phospholipase A₂ receptor will likely provide a novel tool to monitor disease activity and drive rituximab therapy, at least in a subset of patients. Newly developed anti-CD20 antibodies could represent a valuable option for those who fail rituximab therapy. Steroids, alkylating agents, and calcineurin inhibitors should likely be abandoned." @default.
• W2033965404 created "2016-06-24" @default.
• W2033965404 creator A5005075162 @default.
• W2033965404 creator A5023556434 @default.
• W2033965404 creator A5059276594 @default.
• W2033965404 date "2014-11-22" @default.
• W2033965404 modified "2023-10-18" @default.
• W2033965404 title "Rituximab in Primary Membranous Nephropathy: First-Line Therapy, Why Not?" @default.
• W2033965404 cites W1913904590 @default.
• W2033965404 cites W1963592300 @default.
• W2033965404 cites W1966718538 @default.
• W2033965404 cites W1974029083 @default.
• W2033965404 cites W1975736815 @default.
• W2033965404 cites W1986167294 @default.
• W2033965404 cites W1987160165 @default.
• W2033965404 cites W1989529519 @default.
• W2033965404 cites W1991118583 @default.
• W2033965404 cites W2005475183 @default.
• W2033965404 cites W2008615274 @default.
• W2033965404 cites W2016537170 @default.
• W2033965404 cites W2018459774 @default.
• W2033965404 cites W2032192200 @default.
• W2033965404 cites W2034759249 @default.
• W2033965404 cites W2044125631 @default.
• W2033965404 cites W2046330020 @default.
• W2033965404 cites W2048324178 @default.
• W2033965404 cites W2053683902 @default.
• W2033965404 cites W2055812224 @default.
• W2033965404 cites W2063340779 @default.
• W2033965404 cites W2066000834 @default.
• W2033965404 cites W2073033781 @default.
• W2033965404 cites W2084056567 @default.
• W2033965404 cites W2089916413 @default.
• W2033965404 cites W2095787590 @default.
• W2033965404 cites W2107002794 @default.
• W2033965404 cites W2108432978 @default.
• W2033965404 cites W2114360739 @default.
• W2033965404 cites W2114850377 @default.
• W2033965404 cites W2115135526 @default.
• W2033965404 cites W2116986363 @default.
• W2033965404 cites W2122581834 @default.
• W2033965404 cites W2124215501 @default.
• W2033965404 cites W2131815197 @default.
• W2033965404 cites W2133344401 @default.
• W2033965404 cites W2135619376 @default.
• W2033965404 cites W2141219630 @default.
• W2033965404 cites W2142956701 @default.
• W2033965404 cites W2145920236 @default.
• W2033965404 cites W2153604508 @default.
• W2033965404 cites W2157296439 @default.
• W2033965404 cites W2159732018 @default.
• W2033965404 cites W2160726185 @default.
• W2033965404 cites W2162411149 @default.
• W2033965404 cites W2162452494 @default.
• W2033965404 cites W2163100333 @default.
• W2033965404 cites W2164755825 @default.
• W2033965404 cites W2166822765 @default.
• W2033965404 cites W2172275967 @default.
• W2033965404 cites W2318607717 @default.
• W2033965404 cites W3016408864 @default.
• W2033965404 cites W4210977357 @default.
• W2033965404 cites W4235667346 @default.
• W2033965404 cites W4238278421 @default.
• W2033965404 cites W4242848679 @default.
• W2033965404 cites W4245487764 @default.
• W2033965404 doi "https://doi.org/10.1159/000368589" @default.
• W2033965404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25427622" @default.
• W2033965404 hasPublicationYear "2014" @default.
• W2033965404 type Work @default.
• W2033965404 sameAs 2033965404 @default.
• W2033965404 citedByCount "42" @default.
• W2033965404 countsByYear W20339654042014 @default.
• W2033965404 countsByYear W20339654042015 @default.
• W2033965404 countsByYear W20339654042016 @default.
• W2033965404 countsByYear W20339654042017 @default.
• W2033965404 countsByYear W20339654042018 @default.
• W2033965404 countsByYear W20339654042019 @default.
• W2033965404 countsByYear W20339654042020 @default.
• W2033965404 countsByYear W20339654042021 @default.
• W2033965404 countsByYear W20339654042022 @default.
• W2033965404 countsByYear W20339654042023 @default.
• W2033965404 crossrefType "journal-article" @default.
• W2033965404 hasAuthorship W2033965404A5005075162 @default.
• W2033965404 hasAuthorship W2033965404A5023556434 @default.
• W2033965404 hasAuthorship W2033965404A5059276594 @default.
• W2033965404 hasBestOaLocation W20339654041 @default.
• W2033965404 hasConcept C126322002 @default.
• W2033965404 hasConcept C143998085 @default.
• W2033965404 hasConcept C159654299 @default.
• W2033965404 hasConcept C197934379 @default.
• W2033965404 hasConcept C203014093 @default.
• W2033965404 hasConcept C2775946357 @default.
• W2033965404 hasConcept C2777747828 @default.
• W2033965404 hasConcept C2778415529 @default.
• W2033965404 hasConcept C2778930706 @default.
• W2033965404 hasConcept C2780091579 @default.
• W2033965404 hasConcept C2780252810 @default.
• W2033965404 hasConcept C2780368995 @default.

• next